APS vs. IBT, GSD, HEM, AEZS, LTY, BCT, ACST, REUN, NEPT, and ATE
Should you be buying Aptose Biosciences stock or one of its competitors? The main competitors of Aptose Biosciences include IBEX Technologies (IBT), Devonian Health Group (GSD), Hemostemix (HEM), Aeterna Zentaris (AEZS), Liberty Biopharma (LTY), BriaCell Therapeutics (BCT), Acasti Pharma (ACST), Reunion Neuroscience (REUN), Neptune Wellness Solutions (NEPT), and Antibe Therapeutics (ATE). These companies are all part of the "biotechnology" industry.
Aptose Biosciences vs.
IBEX Technologies (CVE:IBT) and Aptose Biosciences (TSE:APS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, community ranking, earnings, valuation and risk.
IBEX Technologies has a net margin of 53.78% compared to Aptose Biosciences' net margin of 0.00%. Aptose Biosciences' return on equity of 1,017.48% beat IBEX Technologies' return on equity.
In the previous week, Aptose Biosciences had 3 more articles in the media than IBEX Technologies. MarketBeat recorded 3 mentions for Aptose Biosciences and 0 mentions for IBEX Technologies. Aptose Biosciences' average media sentiment score of 0.07 beat IBEX Technologies' score of 0.00 indicating that Aptose Biosciences is being referred to more favorably in the news media.
IBEX Technologies has higher revenue and earnings than Aptose Biosciences. Aptose Biosciences is trading at a lower price-to-earnings ratio than IBEX Technologies, indicating that it is currently the more affordable of the two stocks.
IBEX Technologies has a beta of -0.05, meaning that its share price is 105% less volatile than the S&P 500. Comparatively, Aptose Biosciences has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500.
Aptose Biosciences received 177 more outperform votes than IBEX Technologies when rated by MarketBeat users. Likewise, 72.11% of users gave Aptose Biosciences an outperform vote while only 57.38% of users gave IBEX Technologies an outperform vote.
19.1% of IBEX Technologies shares are held by institutional investors. Comparatively, 15.1% of Aptose Biosciences shares are held by institutional investors. 25.4% of IBEX Technologies shares are held by insiders. Comparatively, 17.1% of Aptose Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
IBEX Technologies beats Aptose Biosciences on 8 of the 14 factors compared between the two stocks.
Get Aptose Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for APS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aptose Biosciences Competitors List
Related Companies and Tools
This page (TSE:APS) was last updated on 2/22/2025 by MarketBeat.com Staff
